Cardiome Pharma (CRME) Announces Vernakalant Met Phase 3 Primary Endpoint European Comparator Study
Tweet Send to a Friend
Cardiome Pharma Corp. (NASDAQ: CRME) today announced that the recently-completed Phase 3 European Comparator Study (the AVRO study) evaluating vernakalant ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
